Product Center
The research project on pregnant women receiving the quadrivalent influenza virus subunit vaccine has achieved interim progress
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-05
- Views:
(Summary description)Recently, a mid-term progress summary meeting for the research project on the safety and immunogenicity of the quadrivalent influenza virus subunit vaccine (HRK-X®) in pregnant women was grandly held at the First Affiliated Hospital of Chongqing Medical University.
The research project on pregnant women receiving the quadrivalent influenza virus subunit vaccine has achieved interim progress
(Summary description)Recently, a mid-term progress summary meeting for the research project on the safety and immunogenicity of the quadrivalent influenza virus subunit vaccine (HRK-X®) in pregnant women was grandly held at the First Affiliated Hospital of Chongqing Medical University.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-05 08:55
- Views:
Recently, a mid-term progress summary meeting for the research project on the safety and immunogenicity of the quadrivalent influenza virus subunit vaccine (HRK-X®) in pregnant women was grandly held at the First Affiliated Hospital of Chongqing Medical University.
This study was initiated on March 1, 2025, by the company in collaboration with the First Affiliated Hospital of Chongqing Medical University and the Yuzhong District Center for Disease Control and Prevention in Chongqing. The commencement of this research marks a significant milestone in the prevention and control of influenza among pregnant women in China, providing crucial data support to enhance the vaccination rate of influenza vaccines among pregnant women, reduce maternal and infant health risks associated with influenza, and establish a protective barrier for maternal health during pregnancy. It also fills the gap in scientific evidence from the Chinese population, reinforcing the international consensus that "receiving the influenza vaccine during pregnancy is safe.".
Pregnant women are one of the high-risk groups for influenza and related complications. During pregnancy, various physiological and immune system changes increase their susceptibility to the flu virus, leading to relatively severe clinical symptoms upon infection. Research has found that pregnant women not only face a higher risk of severe illness and death compared to non-pregnant individuals but also an increased likelihood of adverse pregnancy outcomes (such as miscarriage, premature birth, and congenital fetal defects).
By receiving the quadrivalent influenza virus subunit vaccine, pregnant women can significantly reduce their risk of contracting the flu, greatly lowering the likelihood of severe illness, premature birth, stillbirth, and congenital fetal defects. Additionally, maternal antibodies provide protection for the developing fetus and newborns aged 0 to 6 months.
The quadrivalent influenza virus subunit vaccine (HRK-X®) employs a unique process to extract key effective antigens (HA and NA) from the influenza virus. It ensures high purity (≥85%) and excellent safety while demonstrating superior immunogenicity. The product's multiple quality standards exceed those of the Chinese Pharmacopoeia and European Pharmacopoeia, reaching internationally advanced levels. The newly released 《Chinese Influenza Vaccine Prevention and Vaccination Technical Guidelines (2025–2026)》also includes Phase III clinical data for the quadrivalent influenza virus subunit vaccine across all populations, noting that compared to split vaccines, subunit vaccines remove internal viral proteins, resulting in higher purity of antigenic active components and better safety.
In September this year, this product was approved for use in individuals aged 6 months and above, becoming the first and only quadrivalent influenza virus subunit vaccine approved for the entire population at full dosage in China. This high-quality vaccine, featuring high purity, low adverse reactions, excellent safety, and superior immunogenicity, aligns with global vaccine development trends by standardizing vaccine formulations for all individuals aged 6 months and above. It significantly enhances the convenience of vaccination and management, providing broader population coverage and more effective immune protection for influenza prevention and control in China.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
